Fast Neuroprotection (Fast-NPRX) for Acute Ischemic Stroke Victims: The Time for Treatment Is Now

Translational Stroke Research

Volumn 4, Issue 6, 2013, Pages 704-709

  Lapchak, Paul A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; MAGNESIUM SULFATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TENECTEPLASE;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EDITORIAL; FIBRINOLYTIC THERAPY; FOLLOW UP; FUNDING; GOLD STANDARD; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROPROTECTION; PHARMACY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; STROKE PATIENT; STUDY DESIGN; TIME TO TREATMENT; TRANSCRANIAL COLOR CODED SONOGRAPHY; TRANSCRANIAL DOPPLER; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANIMALS; BRAIN DAMAGE, CHRONIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; EMERGENCY MEDICINE; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84888308371     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0303-0     Document Type: Editorial

References (89)

1. Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3): 279-85.
2. Lapchak PA, Zhang JH. Resolving the negative data publication dilemma in translational stroke research. Transl Stroke Res. 2011;2(1): 1-6.
3. Lapchak PA. Emerging therapies: pleiotropic multi-target drugs to treat stroke victims. Transl Stroke Res. 2011;2(2): 129-35.
4. Fagan SC, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res. 2013;4(3): 322-7.
5. Bahjat FR, Gesuete R, Stenzel-Poore MP. Steps to translate preconditioning from basic research to the clinic. Transl Stroke Res. 2013;4(1): 89-103.
6. Winters A, Taylor JC, Ren M, Ma R, Liu R, Yang SH. Transient focal cerebral ischemia induces long-term cerebral vasculature dysfunction in a rodent experimental stroke model. Transl Stroke Res. 2012;3(2): 279-85.
7. Turner RJ, Jickling GC, Sharp FR. Are underlying assumptions of current animal models of human stroke correct: from STAIRs to high hurdles? Transl Stroke Res. 2011;2(2): 138-43.
8. Tajiri N, Dailey T, Metcalf C, Mosley YI, Lau T, Staples M, et al. In vivo animal stroke models: a rationale for rodent and non-human primate models. Transl Stroke Res. 2013;4(3): 308-21.
9. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2): 96-107.
10. Ahmad M, Graham SH. Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res. 2010;1(2): 74-84.
11. Vemuganti R. The microRNAs and stroke: no need to be coded to be counted. Transl Stroke Res. 2010;1(3): 158-60.
12. Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, Johnson MH, et al. Neurovascular injury in acute hyperglycemia and diabetes: a comparative analysis in experimental stroke. Transl Stroke Res. 2011;2(3): 391-8.
13. Davis CM, Fairbanks SL, Alkayed NJ. Mechanism of the sex difference in endothelial dysfunction after stroke. Transl Stroke Res. 2013;4(4): 381-9.
14. Herson PS, Palmateer J, Hurn PD. Biological sex and mechanisms of ischemic brain injury. Transl Stroke Res. 2013;4(1): 413-9.
15. Fagan SC, Cronic LE, Hess DC. Minocycline development for acute ischemic stroke. Transl Stroke Res. 2011;2(2): 202-8.
16. Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4(4): 432-46.
17. Huang B, Khatibi NH, Tong L, Yan P, Xie P, Zhang JH. Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study. Transl Stroke Res. 2010;1(2): 108-12.
18. Switzer JA, Sikora A, Ergul A, Waller JL, Hess DC, Fagan SC. Minocycline prevents IL-6 increase after acute ischemic stroke. Transl Stroke Res. 2012;3(3): 363-8.
19. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6): 588-600.
20. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6): 562-71.
21. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12): e647-56.
22. Saver JL. Targeting the brain: neuroprotection and neurorestoration in ischemic stroke. Pharmacotherapy. 2010;30(7 Pt 2): 62S-9.
23. Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother. 2007;7(4): 333-7.
24. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5): 1227-31.
25. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1): 66-73.
26. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2): 141-50.
27. Kasner SE, Rose DZ, Skokan A, Walker MG, Shi J, Streeter J, et al. Transcranial laser therapy and infarct volume. Stroke. 2013;44(7): 2025-7. doi: 10. 1161/STROKEAHA. 113. 000870.
28. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009;40(4): 1359-64.
29. Photothera. PhotoThera NEST-3 trial halted due to futility. 2013 http://www. tsijournal. com/clinical-trial-updates-body. Accessed 17 Oct 2013.
30. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24): 1581-7.
31. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12): 1099-107.
32. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology. 2009;72(10): 915-21.
33. Haley Jr EC, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4): 707-11.
34. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1): 154-9.
35. O'Collins VE, Donnan GA, Howells DW. History of animal models of stroke. Int J Stroke. 2011;6(1): 77-8.
36. Casals JB, Pieri NC, Feitosa ML, Ercolin AC, Roballo KC, Barreto RS, et al. The use of animal models for stroke research: a review. Comp Med. 2011;61(4): 305-13.
37. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3): 467-77.
38. Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs. 2001;15(3): 165-74.
39. Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci. 2012;13(9): 11753-72.
40. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28(1): 217-9.
41. Savitz SI. Cosmic implications of NXY-059. Stroke. 2009;40(3 Suppl): S115-8.
42. Meloni BP, Cross JL, Brookes LM, Clark VW, Campbell K, Knuckey NW. FAST-Mag protocol with or without mild hypothermia (35 degrees C) does not improve outcome after permanent MCAO in rats. Magnes Res. 2013;26(2): 67-73. Off Org Int Soc Dev Res Magnes.
43. Gorelick PB, Ruland S. IMAGES and FAST-MAG: magnesium for acute ischaemic stroke. Lancet Neurol. 2004;3(6): 330.
44. Saver JL, Kidwell C, Eckstein M, Starkman S, Investigators F-MPT. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke. 2004;35(5): e106-8.
45. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30, 000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41(7): 1431-9.
46. Sanossian N, Starkman S, Eckstein M, Stratton S, Pratt F, Conwit R, et al. Intercontinental elicitation of informed consent for enrollment in stroke research. Cerebrovasc Dis. 2010;30(3): 323-4.
47. Sanossian N, Starkman S, Liebeskind DS, Ali LK, Restrepo L, Hamilton S, et al. Simultaneous ring voice-over-Internet phone system enables rapid physician elicitation of explicit informed consent in prehospital stroke treatment trials. Cerebrovasc Dis. 2009;28(6): 539-44.
48. Schlachetzki F, Herzberg M, Holscher T, Ertl M, Zimmermann M, Ittner KP, et al. Transcranial ultrasound from diagnosis to early stroke treatment: part 2: prehospital neurosonography in patients with acute stroke: the Regensburg stroke mobile project. Cerebrovasc Dis. 2012;33(3): 262-71.
49. Holscher T, Schlachetzki F, Zimmermann M, Jakob W, Ittner KP, Haslberger J, et al. Transcranial ultrasound from diagnosis to early stroke treatment. 1. Feasibility of prehospital cerebrovascular assessment. Cerebrovasc Dis. 2008;26(6): 659-63.
50. Holscher T, Dunford JV, Schlachetzki F, Boy S, Hemmen T, Meyer BC, et al. Prehospital stroke diagnosis and treatment in ambulances and helicopters-a concept paper. Am J Emerg Med. 2013;31(4): 743-7.
51. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2): 181-98.
52. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13): 1317-29.
53. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4. 5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40(7): 2438-41.
54. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010;5(7): 406-9.
55. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36(6): 1232-40.
56. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovasc Qual Outcome. 2013;6(5): 543-9.
57. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4. 5 Hours After Onset of Acute Ischemic Stroke. Ann Emerg Med. 2012.
58. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727): 1695-703.
59. Desai JA, Smith EE. Prenotification and other factors involved in rapid tPA administration. Curr Atheroscler Rep. 2013;15(7): 337.
60. Olson DM, Constable M, Britz GW, Lin CB, Zimmer LO, Schwamm LH, et al. A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke. J Neurosci Nurs. 2011;43(6): 329-36.
61. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: stroke initiative. Stroke. 2011;42(10): 2983-9.
62. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7): 750-8.
63. Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2013;5, CD000514.
64. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3. 0-4. 5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12): 1095-102.
65. Ricci S, Cenciarelli S, Mazzoli T. Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane review: PROS. Intern Emerg Med. 2013. doi: 10. 1007/s11739-013-0987-x.
66. Costantino G, Podda GM, Bonzi M, Sbrojavacca R, Gruppo di Autoformazione Metodologica. Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: cons. Intern Emerg Med. 2013. doi: 10. 1007/s11739-013-0986-y.
67. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23): 2480-8.
68. Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3): 841-3.
69. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419): 187-91.
70. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12): 2752-8.
71. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40(7): 2594-600.
72. McKim Jr JM. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen. 2010;13(2): 188-206.
73. Lapchak PA, KcKim JM. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Transl Stroke Res. 2011;2(1): 51-9.
74. Thaul S. How FDA approves drugs and regulates their safety and effectiveness. 2012. http://www. fas. org/sgp/crs/misc/R41983. pdf, Accessed 17 Oct 2013.
75. FDA. The FDA's drug review process: ensuring drugs are safe and effective. 2012. http://www. fda. gov/drugs/resourcesforyou/consumers/ucm143534. htm, Accessed 17 Oct 2013.
76. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123(4): e18-209.
77. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update. Circulation. 2011. doi: 10. 1161/CIR. 0b013e31823ac046.
78. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3): 480-6.
79. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7): 2064-89.
80. Worldometer. http://www. worldometers. info/world-population/. 2013. Accessed 17 Oct 2013.
81. Saver JL. Time is brain-quantified. Stroke. 2006;37(1): 263-6.
82. Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007;38(6): 1843-9.
83. Leonardo CC, Robbins S, Dore S. Translating basic science research to clinical application: models and strategies for intracerebral hemorrhage. Front Neurol. 2012;3: 85.
84. Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012;9(2): 371-9.
85. Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012;4(154): 154ra33.
86. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener. 2011;6(1): 11.
87. Bordet R, Ouk T, Onteniente B, Charriaut-Marlangue C, Heurteaux C. Cerebral ischaemia: tomorrow's therapeutic tracks. Med Sci (Paris). 2009;25(10): 847-54.
88. Lo EH, Rosenberg GA. The neurovascular unit in health and disease: introduction. Stroke. 2009;40(3 Suppl): S2-3.
89. Ferguson KN, Kidwell CS, Starkman S, Saver JL. Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis. 2004;13(3): 109-12.